Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In univariate analysis (Table 3), education level (P = .026), azathioprine use (P = .019), any micronutrient deficiency (P = .007), self-reported vitamin D deficiency in the preceding 3 months (P = .011), and iron deficiency (P = .004) were associated with disability status.

Source: Risk factors associated with IBD-related disability. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A cross-sectional study was conducted among patients with a confirmed diagnosis of Crohn’s disease (CD) or ulcerative colitis for at least six months.

Source: Abstract.

For analytic purposes, participants were categorized as having high disability (IBD Disk score >40) or lower disability burden (IBD Disk score ≤40).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Disability among Palestinian patients with inflammatory bowel disease: evaluation using the IBD Disk and identification of associated factors

Cross-sectional study · Crohn's & Colitis 360 · 2026

Original publication title

Disability among Palestinian patients with inflammatory bowel disease: evaluation using the IBD Disk and identification of associated factors

Ahmed Quraish; Ro’ya Khanfar; Karmil Kharouf; Sami Salous; Dala Quraish; Qusay Abdoh

© The Author(s) 2026. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This study revealed that the prevalence of IBD disability in Palestine was 58.1%, with joint pain being the domain with the highest scores. This highlights the substantial disability burden observed among Palestinian patients with IBD. Azathioprine use was associated with lower disability scores, whereas self-reported vitamin D deficiency in the preceding 3 months was associated with higher disability. In addition, cigarettes smoked per day showed a weak positive correlation with IBD Disk scores among patients with CD, whereas smoking status was not independently associated with high disability in the multivariable model.

These findings should be interpreted cautiously given the cross-sectional design, self-reported exposures, and absence of objective disease activity measures. All in all, implementing routine disability assessment using the IBD Disk may support early identification of high-risk patients and guide more targeted clinical interventions to improve outcomes for individuals living with IBD.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic, relapsing-remitting disease characterized by alternating active and remission episodes of intestinal inflammation.1 A complex interplay of host genetic, microbial, and environmental variables contributes to its pathogenesis. However, there are still unanswered questions regarding the etiology and behavior of the disease.2 Globally, the burden of IBD is a significant public health challenge. This burden is mainly due to the increased prevalence, especially in newly industrialized areas in South America, Asia, and Africa, which places an increasing social and financial strain on society, governments, and healthcare systems.3 to 5 Compared with the general population, patients with IBD experience reduced quality of life and higher rates of disability.6 to 8

Even though IBD is linked to substantial morbidity and disability, which at times necessitates hospitalization and surgery, physicians frequently underestimate the impact of this disease on their patients’ lives.9,10 IBD-related disability occurs due to several factors, with the nature of it being an incurable relapsing-remitting disease with heterogeneous clinical presentation being a major one. Another factor is its association with extraintestinal systemic symptoms such as fatigue and occasionally fever besides cutaneous, hepatobiliary, rheumatological, and ophthalmological manifestations.11 to 13 Physical, psychological, familial, and social aspects of this illness also play a role in disability.14,15

In recent years, preventing disability has garnered increasing attention as there has been a significant change in the treatment paradigm from symptom control to complete disease control (clinical and endoscopic relief). The end goal of such change has been to stop the disease’s progression and preventing intestinal damage and subsequently the ensuing disability.16 The updated Selecting Therapeutic Targets in Inflammatory Bowel Disease further highlights that in addition to clinical remission and endoscopic healing, major long-term goals focus on the absence of disability, restoration of quality of life, and normal growth in children.17

Adopting the World Health Organization (WHO) definition, IBD-related disability includes restrictions on one’s ability to pursue education and employment, exclusion from social and economic activities, and impairments of one’s physical and psychological functioning.18 In an effort to measure disability, the IBD Disability Index (IBD-DI) was developed in collaboration with the WHO.19 It allows patients to be followed to evaluate the effects of treatment plans and pathways on the progression of illnesses, the degree of disability, and the overall impact of the condition.10 While the IBD-DI is a useful tool for assessing disability, its length often limits its use in busy clinical settings.

Recently, a shortened self-administered tool derived from the IBD-DI, called the IBD Disk, was developed. This tool was created for routine clinical assessment as a more convenient way of capturing disability caused by IBD.20 Despite the increasing burden of IBD in many regions, including the Middle East, IBD-related disability remains an understudied issue. To our knowledge, there has been no study assessing IBD disability using the IBD Disk in Palestine. Therefore, this study aimed to determine the prevalence of IBD-related disability among Palestinian patients using the IBD Disk and to identify the risk factors associated with higher disability.

Source: Introduction Source: Introduction Source: Introduction Source: Introduction

Study methods

What methods does the paper describe?

Study design and setting

A cross-sectional study was conducted in the Northern West Bank, Palestine from April 2025 to September 2025. The study assessed IBD-related disability and associated risk factors among patients with IBD attending follow-up visits at multiple general outpatient gastroenterology clinics across the Northern West Bank. Recruitment was clinic-based and involved patients receiving follow-up care in general gastroenterology practice rather than in specialized IBD referral clinics or through a centralized registry or database.

Participants and sampling

A convenience sampling method was employed, where all those attending outpatient follow-up visits who met the eligibility criteria were invited to participate in the study. Participants included in the study were those with a confirmed diagnosis of CD or UC established by a gastroenterologist based on endoscopic and histologic evaluation. Inclusion criteria also included disease duration ≥6 months. All ages were included provided that they were able to independently complete the Arabic questionnaire. Patients who had a diagnosis other than IBD, filled incomplete questionnaires, or were unable to complete the questionnaire due to cognitive or language limitations, were excluded from the study.

Because recruitment was based on convenience sampling during clinic attendance and the number of eligible patients approached was not systematically recorded, a formal survey response rate could not be calculated. Recruitment was limited to patients attending outpatient follow-up visits during the study period.

The sample size for this study was calculated using the Raosoft sample size calculator. Based on an estimated population of 367 patients, assuming a 95% confidence level, a 5% margin of error, and an expected outcome prevalence of 19% derived from a Saudi IBD Disk-based study, the minimum required sample size was 145 patients.21,22 The final sample size collected was 179, exceeding the minimum required sample size.

Data collection and study variables

Data were collected using a structured Arabic questionnaire distributed as a Google Form. Questionnaires were completed by participants during clinic visits with trained researchers available to clarify any items. All variables were obtained through patient self-report, including height and weight, from which body mass index (BMI) was calculated. The questionnaire was made up of several sections covering sociodemographic characteristics, lifestyle factors, anthropometric information, disease-related variables, treatment history, comorbidities, micronutrient deficiencies, and the IBD Disk instrument. All reported clinical characteristics, comorbidities, treatment exposures, smoking variables, and hospitalization or surgical history were based on participant self-report and were not independently verified using medical records, laboratory data, or endoscopic/biochemical assessments.

Self-reported micronutrient deficiencies referred to the preceding 3 months. Current supplement and medication use was recorded separately. Accordingly, objective disease activity indices such as clinical scores, inflammatory biomarkers, or endoscopic severity measures were not available for analysis.

Collected variables included demographic and clinical characteristics including age, gender, marital status, education level, BMI, smoking status (cigarettes), number of cigarettes per day, waterpipe/vape use, disease type (CD vs UC), disease duration, history of surgery, history of hospitalization, adherence to treatment, adherence to follow-up visits, use of 5-aminosalicylates (5-ASA), use of azathioprine, use of biologic therapy, use of systemic corticosteroids, use of other medications, presence of other chronic diseases (diabetes mellitus, hypertension, dyslipidemia, Behçet’s disease, rheumatoid arthritis, psoriasis, osteoporosis, and others), and presence of any self-reported nutrient deficiency in the preceding 3 months (vitamin D deficiency, iron deficiency, vitamin B12 deficiency, calcium deficiency, and other deficiencies).

The primary outcome was IBD-related disability, measured using the total IBD Disk score (0 to 100). For analytic purposes, participants were categorized as having high disability (IBD Disk score >40) or lower disability burden (IBD Disk score ≤40).

IBD Disk instrument

The IBD Disk is made up of 10 domains. The components include abdominal pain, regulating defecation, interpersonal interactions, education and work, sleep, energy, emotions, body image, sexual functions, and joint pain. Sub-scores for each of the ten components in the IBD Disk questionnaire provide information regarding the patient’s impairment, systemic symptoms, manifestations, and overall effects on social life. Responses are provided on a scale ranging from 0 to 10 (0 = no burden; 10 = maximal burden). The total score was out of 100; the best score is 0, while the worst score is 100.

A cutoff score of >40 was used to determine high disability as it has been linked to a high daily-life burden from IBD.23

The original English IBD Disk questionnaire was translated into Arabic using a forward-backward translation process conducted by independent bilingual translators. The final translated version was then reviewed and approved by a gastroenterologist to confirm its clinical relevance and conceptual accuracy. Prior to data collection, the translated questionnaire was pilot tested with 10 patients with IBD to assess item clarity, comprehension, wording, and feasibility of completion in the target patient population. A small sample of 10 patients with IBD was considered appropriate for this preliminary linguistic and face-validity pretest because the aim was to identify major comprehension or wording problems before full data collection, rather than to perform formal psychometric validation.

As no major comprehension difficulties were identified and only minor wording revisions were required, the pilot sample was not expanded before full recruitment. Internal consistency was subsequently assessed in the full study sample using Cronbach’s alpha, which yielded a value of 0.89.

Statistical analysis

For data analysis, we used IBM Statistical Package for the Social Sciences. Descriptive statistics were calculated and presented as frequencies and percentages, while continuous variables were summarized as means ± standard deviations. Normality of continuous variables was assessed using the Shapiro: Wilk test. Because total IBD Disk score and individual domain scores were not normally distributed, comparisons between patients with CD and UC were performed using the Mann: Whitney U test. Pearson’s chi-square test and Fisher’s exact test (when expected cell counts were less than 5) were used to determine the associations between various predictor variables and outcome (high disability vs lower disability burden).

Independent predictors of disability were identified using multivariable binary logistic regression with results reported as adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Variables with a P-value < .20 in the univariate analysis, as well as clinically relevant factors identified, were entered into the multivariable binary logistic regression model. Spearman’s rank correlation was used to assess associations between the continuous IBD Disk score and continuous variables. Exploratory subgroup analysis was additionally performed by stratifying patients according to biologic therapy status and prior surgical history.

Differences in total IBD Disk score and individual domains were also assessed using the Mann: Whitney U test. A P-value less than .05 was considered significant.

Ethical considerations

IRB (Institutional Review Board) approval was obtained prior to questionnaire distribution [Reference: Med. March. 2025/36]. Written informed consent was obtained from all adult participants prior to participation. For participants aged below 18 years, written informed consent was obtained from a parent or legal guardian, and participant assent was obtained when applicable. Confidentiality, anonymity, and voluntary participation were ensured.

Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods

Results: Characteristics of the patients

A total of 179 patients with IBD were included in this study. The mean age was 33.68 ± 12.27 and 93 (52.0%) were male. Most patients, 111 (62.0%) were married and 102 (57.0%) had university degrees. As for disease distribution, the majority of patients, 106 (59.2%) had CD, while 73 (40.8%) were diagnosed with UC. The mean duration of the disease was 8.43 ± 6.68 years.

In terms of lifestyle factors, 66 (36.9%) were cigarette smokers with a mean of 4.29 ± 10.17 cigarettes per day. Nearly half of the patients, 88 (49.4%) had a normal BMI while 78 (43.8%) were overweight or obese. The mean BMI was 26.08 ± 4.73 kg/m2. Comorbidities reported by patients were relatively infrequent. Hypertension 10 (5.6%) and rheumatoid arthritis 8 (4.5%) were the most common. Other comorbidities included diabetes mellitus 7 (3.9%), dyslipidemia 5 (2.8%), psoriasis 3 (1.7%), osteoporosis 2 (1.1%), and Behçet’s disease 2 (1.1%).

Regarding treatment, 58 (32.4%) were using 5-aminosalicylates, 68 (38.0%) were using azathioprine, 48 (26.8%) were on biologic treatment, and 19 (10.6%) were taking systemic corticosteroids. Self-reported medication and follow-up adherence was high, with (87.7%) reporting commitment to treatment and 127 (70.9%) committed to regular follow-ups.

More than half of the patients, 115 (64.2%) had a history of IBD-related hospitalization. A total of 31 (17.3%) patients reported having IBD-related surgery, with 19 (61.3%) of them undergoing bowel resections. More details are seen in Table 1.

Table 1

Demographic and clinical characteristics of the study participants (N = 179).

VariableTotal: n (%) or mean ± SD
Age, years (mean ± SD) 33.68 ± 12.27
Age groups
  18 and younger 9 (5.0)
  19-30 71 (39.7)
  31-50 78 (43.6)
  51 and older 21 (11.7)
Gender
  Male 93 (52.0)
  Female 86 (48.0)
Marital status
  Single 66 (36.9)
  Married 111 (62.0)
  Divorced 1 (0.6)
  Widow 1 (0.6)
Years of marriage, years (mean ± SD) 15.33 ± 11.42
Education
  Primary school 8 (4.5)
  High school 61 (34.1)
  University 102 (57.0)
  Postgraduate 8 (4.5)
Disease type
  Crohn’s disease 106 (59.2)
  Ulcerative colitis 73 (40.8)
Disease duration, years (mean ± SD) 8.43 ± 6.68
Disease duration
  Less than 5 years 53 (29.6)
  5-10 years 82 (45.8)
  more than 10 years 44 (24.6)
Committed to treatment
  Yes 157 (87.7)
  No 22 (12.3)
Committed to regular follow-ups
  Yes 127 (70.9)
  No 52 (29.1)
Reason for not being committed to doctor visit
  Stable 26 (14.5)
  Medications not available 1 (0.6)
  Difficult transportation 9 (5)
  Not committed 6 (3.4)
  Financial 7 (3.9)
Medication
  5-aminosalicylates 58 (32.4)
  Azathioprine 68 (38.0)
  Biologic 48 (26.8)
  Systemic corticosteroids 19 (10.6)
  Other medications 34 (19.6)
Hospitalization
  No 64 (35.7)
  Yes 115 (64.2)
Had surgery
  No 148 (82.7)
  Yes 31 (17.3)
Type of surgery
  Bowel resection 19 (10.6)
  Hemorrhoid/Fistula 5 (2.8)
  Other abdominal surgery (appendix, cholecystectomy) 7 (3.9)
Other chronic diseases
  Diabetes Mellitus 7 (3.9)
  Hypertension 10 (5.6)
  Dyslipidemia 5 (2.8)
  Behçet’s disease 2 (1.1)
  Rheumatoid arthritis 8 (4.5)
  Psoriasis 3 (1.7)
  Osteoporosis 2 (1.1)
  Others 15 (8.4)
BMI
  Underweight 12 (6.7)
  Normal 88 (49.4)
  Overweight 46 (25.8)
  Obese 32 (18)
Cigarette smoker
  No 113 (63.1)
  Yes 66 (36.9)
Cigarettes per day, number/day (mean ± SD) 4.29 ± 10.17
Smoker (other than cigarette)
  Nothing 149 (83.0)
  Waterpipe 27 (15.1)
  Vape 3 (1.7)

Abbreviations: BMI, body mass index; SD, standard deviation.

Source: Characteristics of the patients Source: Characteristics of the patients Source: Characteristics of the patients Source: Characteristics of the patients Source: Characteristics of the patients

Results: IBD-related disability scores

The mean total IBD Disk score in this study was 45.31 ± 23.2. Using a cutoff value of more than 40 to define high disability, 104 (58.1%) patients were classified as having high disability, whereas 75 (41.9%) were classified as having lower disability burden (IBD Disk score ≤40). The highest mean scores observed across the 10 IBD Disk domains were joint pain with a mean of 6.06 ± 3.32, tiredness/lack of energy (5.70 ± 3.33), emotional wellbeing (5.41 ± 3.49), and sleep disturbances (5.31 ± 3.46).

The lowest score was observed in the sexual domain (2.46 ± 2.43). A visual representation of the overall disability profile is provided in Figure 1, which demonstrates the distribution of mean domain scores across the IBD Disk. Mean total IBD Disk scores were similar between patients with CD and those with UC (45.92 ± 23.07 vs 44.42 ± 23.52, P = .564). No significant differences were observed between disease types across any individual IBD Disk domain scores (Table 2).

Figure 1

Radar plot showing mean IBD Disk domain scores among Palestinian patients with inflammatory bowel disease. Higher scores indicate greater impairment in the corresponding domain (scale 0-10). IBD, inflammatory bowel disease.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 2

IBD Disk total and domain scores overall and by disease type.

VariableTotal, mean ± SDUC, mean ± SDCD, mean ± SD P-value
Total IBD Disk score 45.31 ± 23.2044.42 ± 23.5245.92 ± 23.07.564
Abdominal pain 4.99 ± 3.164.52 ± 2.955.31 ± 3.26.086
Regulating defecation 3.55 ± 3.053.51 ± 3.073.58 ± 3.06.736
Interpersonal interactions 3.56 ± 3.173.93 ± 3.273.30 ± 3.09.172
Education and work 4.18 ± 3.434.15 ± 3.334.21 ± 3.51.983
Sleep 5.31 ± 3.464.92 ± 3.385.58 ± 3.50.200
Energy 5.70 ± 3.335.45 ± 3.125.88 ± 3.47.321
Emotions 5.41 ± 3.495.47 ± 3.125.37 ± 3.52.770
Body image 4.08 ± 3.254.04 ± 3.124.11 ± 3.35.982
Sexual functions 2.46 ± 2.432.42 ± 2.252.49 ± 2.55.775
Joint pain 6.06 ± 3.326.01 ± 3.426.09 ± 3.26.863

Note: Data are presented as mean ± SD. P-values represent comparisons between Crohn’s disease and ulcerative colitis using the Mann: Whitney U test.

Source: IBD-related disability scores Source: IBD-related disability scores Source: IBD-related disability scores

Risk factors associated with IBD-related disability

Results: Risk factors associated with IBD-related disability

In univariate analysis (Table 3), education level (P = .026), azathioprine use (P = .019), any micronutrient deficiency (P = .007), self-reported vitamin D deficiency in the preceding 3 months (P = .011), and iron deficiency (P = .004) were associated with disability status. Azathioprine use was associated with a lower proportion of high disability, whereas any micronutrient deficiency, self-reported vitamin D deficiency in the preceding 3 months, and iron deficiency were associated with a higher proportion of high disability.

All other evaluated sociodemographic, clinical, lifestyle, and treatment-related variables were not significantly associated with disability status in univariate analysis.

Table 3

Univariate analysis of factors associated with IBD-related disability.

VariableLower disability burden (IBD Disk score ≤40), n = 75High disability (IBD Disk >40), n = 104 P-value
Age category 18 and younger 3 (4.0)6 (5.8).061a
19-30 31 (41.3)40 (38.5)
31-50 27 (36.0)51 (49.0)
51 and older 14 (18.7)7 (6.7)
Gender Male 40 (53.3)53 (51.0).754a
Female 35 (46.7)51 (49.0)
Marital status Single 26 (34.7)40 (38.5).391b
Married 47 (62.7)64 (61.5)
Divorced 1 (1.3)0 (0.0)
Widow 1 (1.3)0 (0.0)
Education Primary school 5 (6.7)3 (2.9) .026b
High school 17 (22.7)44 (42.3)
University 48 (64.0)54 (51.9)
Postgraduate 5 (6.7)3 (2.9)
Disease type Crohn’s disease 43 (57.3)63 (60.6).663a
Ulcerative colitis 32 (42.7)41 (39.4)
Disease duration Less than 5 years 21 (28.0)32 (30.8).922a
5-10 years 35 (46.7)47 (45.2)
More than 10 years 19 (25.3)25 (24.0)
Committed to treatment No 7 (9.3)15 (14.4).306a
Yes 68 (90.7)89 (85.6)
Committed to regular follow-ups No 16 (21.3)36 (34.6).053a
Yes 59 (78.7)68 (65.4)
Biologic treatment No 53 (70.7)78 (75.0).518a
Yes 22 (29.3)26 (25.0)
5-aminosalicylates No 48 (64.0)73 (70.2).382a
Yes 27 (36.0)31 (29.8)
Systemic steroids No 70 (93.3)90 (86.5).145a
Yes 5 (6.7)14 (13.5)
Azathioprine No 39 (52.0)72 (69.2) .019a
Yes 36 (48.0)32 (30.8)
Other medications No 64 (85.3)81 (77.9).210a
Yes 11 (14.7)23 (22.1)
Hospitalization No 31 (41.3)33 (31.7).126a
Yes 44 (58.7)71 (68.3)
Had surgery No 62 (82.7)86 (82.7).996a
Yes 13 (17.3)18 (17.3)
Type of surgery † Bowel resection 10 (90.9)9 (56.3).143b
Hemorrhoid/Fistula 0 (0.0)5 (31.3)
Other abdominal surgery (appendix, cholecystectomy) 1 (9.1)2 (12.5)
BMI Underweight 3 (4.0)9 (8.7).357a
Normal 35 (46.7)53 (51.0)
Overweight 19 (25.3)27 (26.0)
Obese 17 (22.7)15 (14.4)
Cigarette smoker No 51 (68.0)62 (59.6).251a
Yes 24 (32.0)42 (40.4)
Smoker (other than cigarettes) Nothing 63 (84.0)86 (82.7).086b
Waterpipe 9 (12.0)18 (17.3)
Vape 3 (4.0)0 (0.0)
Diabetes mellitus No 70 (93.3)102 (98.1).132b
Yes 5 (6.7)2 (1.9)
Hypertension No68 (90.7)101 (97.1).097b
Yes7 (9.3)3 (2.9)
Dyslipidemia No73 (97.3)101 (97.1)1.000b
Yes2 (2.7)3 (2.9)
Behçet’s disease No74 (98.7)103 (99.0)1.000b
Yes1 (1.3)1 (1.0)
Rheumatoid arthritis No73 (97.3)98 (94.2).471b
Yes2 (2.7)6 (5.8)
Psoriasis No72 (96.0)104 (100).072b
Yes3 (4.0)0 (0)
Osteoporosis No74 (98.7)103 (99.0)1.000b
Yes1 (1.3)1 (1.0)
Any deficiencies No54 (72.0)54 (51.9) .007a
Yes21 (28.0)50 (48.1)
Calcium deficiency No72 (96.0)100 (96.2)1.000b
Yes3 (4.0)4 (3.8)
B12 deficiency No70 (93.3)89 (85.6).104a
Yes5 (6.7)15 (14.4)
Vitamin D deficiency No68 (90.7)79 (76.0) .011a
Yes7 (9.3)25 (24.0)
Iron deficiency No64 (85.3)69 (66.3) .004a
Yes11 (14.7)35 (33.7)

Note: Data are presented as n (%) within disability category unless otherwise indicated. Micronutrient deficiencies were self-reported and referred to the preceding 3 months. Values in bold indicate statistically significant associations (P < 0.05).

a

Pearson’s chi-square test.

b

Fisher’s exact test.

†

Type-of-surgery percentages are calculated among participants with available surgery subtype data within each disability category (lower disability burden: n = 11; high disability: n = 16).

Source: Risk factors associated with IBD-related disability Source: Risk factors associated with IBD-related disability

Independent predictors of IBD-related disability

Results: Independent predictors of IBD-related disability

In the multivariable binary logistic regression model (Table 4), analysis showed that self-reported vitamin D deficiency in the preceding 3 months remained independently associated with higher odds of high IBD-related disability (aOR 2.93; 95% CI 1.07 to 8.06; P = .037). In contrast, azathioprine use was independently associated with lower odds of high IBD-related disability (aOR 0.421, 95% CI 0.213-0.829, P = .012). No other sociodemographic, clinical, lifestyle, or treatment-related variables included in the model were significantly associated with disability after adjustment.

Table 4

Multivariable logistic regression analysis of factors associated with high IBD-related disability.

VariableCategory aOR 95% CI P-value
Age category 18 and youngerReference
19-300.6770.134-3.429.637
31-500.9370.185-4.748.938
51 and older0.2130.034-1.327.097
Education Primary schoolReference
High school2.9490.569-15.277.198
University1.2100.243-6.016.816
Postgraduate0.9830.102-9.446.988
Vitamin D deficiency NoReference
Yes2.9321.066-8.060 .037
Azathioprine NoReference
Yes0.4210.213-0.829 .012
Gender MaleReference
Female1.0380.497-2.168.922
Smoker NoReference
Yes0.9910.454-2.165.983
Iron deficiency NoReference
Yes2.0560.867-4.878.102

Note: Reference category shown for each variable. Vitamin D and iron deficiencies were self-reported and referred to the preceding 3 months. Values in bold indicate statistically significant associations (P < 0.05).

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval.

Source: Independent predictors of IBD-related disability Source: Independent predictors of IBD-related disability

Results: Correlation analysis

A Spearman’s correlation analysis (Table 5) was performed to assess the relationship between IBD-related disability scores and continuous variables. Among patients with CD, the number of cigarettes smoked per day showed a weak but statistically significant positive correlation with IBD Disk scores (ρ = 0.229; P = .018). There were no significant correlations between IBD-related disability and age, disease duration, BMI, or years of marriage.

Table 5

Spearman correlation of total IBD Disk score with selected continuous variables overall and by disease type.

VariableOverall, ρ P-valueCD, ρ P-valueUC, ρ P-value
Age −0.026.7330.000.999−0.060.615
Disease duration (years) −0.082.275−0.185.0580.064.592
BMI −0.043.568−0.096.3310.085.474
Cigarette number per day 0.112.134 0.229 .018 −0.113.340
Years of marriage −0.093.330−0.034.810−0.100.455

Note: Analyses were performed using available data within each group. Values in bold indicate statistically significant associations (P < 0.05).

Abbreviation: ρ, Spearman’s rank correlation coefficient.

Source: Correlation analysis Source: Correlation analysis

What strengths and limitations does the paper describe?

Discussion: What strengths and limitations does the paper describe?

This study has several strengths. It is the first study in Palestine that addresses and measures disability in IBD patients using the IBD-Disk, providing valuable insight from an understudied population. The sample size obtained, exceeding the minimum required sample size, enhances the robustness of the analysis. Additionally, the Arabic version of the IBD Disk used in this study underwent a structured translation and back-translation process, and demonstrated strong internal consistency (Cronbach’s α = 0.89), supporting its reliability for use in this context.

Despite these strengths, this study has several limitations. First, the cross-sectional design does not allow causal inference, and the observed relationships should be interpreted as associations instead. Second, the study relied largely on self-reported data, including treatment history, comorbidities, smoking exposure, hospitalization, surgery, and micronutrient deficiencies, which introduces potential recall and misclassification bias. In particular, vitamin D deficiency was assessed by self-report for the preceding 3 months rather than by laboratory confirmation, and no data were available regarding laboratory values, deficiency severity, or whether the reported deficiency represented prior, persistent, or treated deficiency.

Third, we did not collect objective measures of disease activity such as clinical indices, inflammatory biomarkers, or endoscopic assessments. Accordingly, it was not possible to determine whether the observed disability primarily reflected active intestinal disease, extraintestinal manifestations, psychosocial factors, or a combination of these influences. Because disease activity is strongly associated with disability in IBD, the absence of objective activity data limits interpretation of the observed associations. Fourth, several potentially important predictors of disability were not systematically assessed or comprehensively characterized, including extraintestinal manifestations, depression, anxiety, socioeconomic status, and healthcare-access factors.

These variables may influence disability independently of intestinal disease activity and may have contributed to the burden observed in this cohort. Fifth, we did not collect detailed disease-phenotype data such as disease extent or distribution, which may influence disability burden and could have differed between patient groups. Sixth, detailed treatment characterization, including duration of biologic exposure and combination therapy, was not available. We were also unable to determine whether the relatively low biologic-use rate reflected disease severity, access limitations, or local treatment practices.

Finally, participants were recruited from general outpatient gastroenterology clinics in the Northern West Bank using convenience sampling, which may have introduced selection bias. Although these were general clinics rather than specialized IBD referral clinics, the sample may still overrepresent patients who are more engaged with follow-up care and underrepresent those who do not attend regularly. As a result, the severity profile and disability burden observed in this study may not fully reflect all patients with IBD in the community. This also limits the generalizability of the findings to patients outside this clinic-attending population and to other regions.

Source: Strengths and limitations

Results

Characteristics of the patients

A total of 179 patients with IBD were included in this study. The mean age was 33.68 ± 12.27 and 93 (52.0%) were male. Most patients, 111 (62.0%) were married and 102 (57.0%) had university degrees. As for disease distribution, the majority of patients, 106 (59.2%) had CD, while 73 (40.8%) were diagnosed with UC. The mean duration of the disease was 8.43 ± 6.68 years.

In terms of lifestyle factors, 66 (36.9%) were cigarette smokers with a mean of 4.29 ± 10.17 cigarettes per day. Nearly half of the patients, 88 (49.4%) had a normal BMI while 78 (43.8%) were overweight or obese. The mean BMI was 26.08 ± 4.73 kg/m2. Comorbidities reported by patients were relatively infrequent. Hypertension 10 (5.6%) and rheumatoid arthritis 8 (4.5%) were the most common. Other comorbidities included diabetes mellitus 7 (3.9%), dyslipidemia 5 (2.8%), psoriasis 3 (1.7%), osteoporosis 2 (1.1%), and Behçet’s disease 2 (1.1%).

Regarding treatment, 58 (32.4%) were using 5-aminosalicylates, 68 (38.0%) were using azathioprine, 48 (26.8%) were on biologic treatment, and 19 (10.6%) were taking systemic corticosteroids. Self-reported medication and follow-up adherence was high, with (87.7%) reporting commitment to treatment and 127 (70.9%) committed to regular follow-ups.

More than half of the patients, 115 (64.2%) had a history of IBD-related hospitalization. A total of 31 (17.3%) patients reported having IBD-related surgery, with 19 (61.3%) of them undergoing bowel resections. More details are seen in Table 1.

Table 1

Demographic and clinical characteristics of the study participants (N = 179).

VariableTotal: n (%) or mean ± SD
Age, years (mean ± SD) 33.68 ± 12.27
Age groups
  18 and younger 9 (5.0)
  19-30 71 (39.7)
  31-50 78 (43.6)
  51 and older 21 (11.7)
Gender
  Male 93 (52.0)
  Female 86 (48.0)
Marital status
  Single 66 (36.9)
  Married 111 (62.0)
  Divorced 1 (0.6)
  Widow 1 (0.6)
Years of marriage, years (mean ± SD) 15.33 ± 11.42
Education
  Primary school 8 (4.5)
  High school 61 (34.1)
  University 102 (57.0)
  Postgraduate 8 (4.5)
Disease type
  Crohn’s disease 106 (59.2)
  Ulcerative colitis 73 (40.8)
Disease duration, years (mean ± SD) 8.43 ± 6.68
Disease duration
  Less than 5 years 53 (29.6)
  5-10 years 82 (45.8)
  more than 10 years 44 (24.6)
Committed to treatment
  Yes 157 (87.7)
  No 22 (12.3)
Committed to regular follow-ups
  Yes 127 (70.9)
  No 52 (29.1)
Reason for not being committed to doctor visit
  Stable 26 (14.5)
  Medications not available 1 (0.6)
  Difficult transportation 9 (5)
  Not committed 6 (3.4)
  Financial 7 (3.9)
Medication
  5-aminosalicylates 58 (32.4)
  Azathioprine 68 (38.0)
  Biologic 48 (26.8)
  Systemic corticosteroids 19 (10.6)
  Other medications 34 (19.6)
Hospitalization
  No 64 (35.7)
  Yes 115 (64.2)
Had surgery
  No 148 (82.7)
  Yes 31 (17.3)
Type of surgery
  Bowel resection 19 (10.6)
  Hemorrhoid/Fistula 5 (2.8)
  Other abdominal surgery (appendix, cholecystectomy) 7 (3.9)
Other chronic diseases
  Diabetes Mellitus 7 (3.9)
  Hypertension 10 (5.6)
  Dyslipidemia 5 (2.8)
  Behçet’s disease 2 (1.1)
  Rheumatoid arthritis 8 (4.5)
  Psoriasis 3 (1.7)
  Osteoporosis 2 (1.1)
  Others 15 (8.4)
BMI
  Underweight 12 (6.7)
  Normal 88 (49.4)
  Overweight 46 (25.8)
  Obese 32 (18)
Cigarette smoker
  No 113 (63.1)
  Yes 66 (36.9)
Cigarettes per day, number/day (mean ± SD) 4.29 ± 10.17
Smoker (other than cigarette)
  Nothing 149 (83.0)
  Waterpipe 27 (15.1)
  Vape 3 (1.7)

Abbreviations: BMI, body mass index; SD, standard deviation.

IBD-related disability scores

The mean total IBD Disk score in this study was 45.31 ± 23.2. Using a cutoff value of more than 40 to define high disability, 104 (58.1%) patients were classified as having high disability, whereas 75 (41.9%) were classified as having lower disability burden (IBD Disk score ≤40). The highest mean scores observed across the 10 IBD Disk domains were joint pain with a mean of 6.06 ± 3.32, tiredness/lack of energy (5.70 ± 3.33), emotional wellbeing (5.41 ± 3.49), and sleep disturbances (5.31 ± 3.46).

The lowest score was observed in the sexual domain (2.46 ± 2.43). A visual representation of the overall disability profile is provided in Figure 1, which demonstrates the distribution of mean domain scores across the IBD Disk. Mean total IBD Disk scores were similar between patients with CD and those with UC (45.92 ± 23.07 vs 44.42 ± 23.52, P = .564). No significant differences were observed between disease types across any individual IBD Disk domain scores (Table 2).

Figure 1

Radar plot showing mean IBD Disk domain scores among Palestinian patients with inflammatory bowel disease. Higher scores indicate greater impairment in the corresponding domain (scale 0-10). IBD, inflammatory bowel disease.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 2

IBD Disk total and domain scores overall and by disease type.

VariableTotal, mean ± SDUC, mean ± SDCD, mean ± SD P-value
Total IBD Disk score 45.31 ± 23.2044.42 ± 23.5245.92 ± 23.07.564
Abdominal pain 4.99 ± 3.164.52 ± 2.955.31 ± 3.26.086
Regulating defecation 3.55 ± 3.053.51 ± 3.073.58 ± 3.06.736
Interpersonal interactions 3.56 ± 3.173.93 ± 3.273.30 ± 3.09.172
Education and work 4.18 ± 3.434.15 ± 3.334.21 ± 3.51.983
Sleep 5.31 ± 3.464.92 ± 3.385.58 ± 3.50.200
Energy 5.70 ± 3.335.45 ± 3.125.88 ± 3.47.321
Emotions 5.41 ± 3.495.47 ± 3.125.37 ± 3.52.770
Body image 4.08 ± 3.254.04 ± 3.124.11 ± 3.35.982
Sexual functions 2.46 ± 2.432.42 ± 2.252.49 ± 2.55.775
Joint pain 6.06 ± 3.326.01 ± 3.426.09 ± 3.26.863

Note: Data are presented as mean ± SD. P-values represent comparisons between Crohn’s disease and ulcerative colitis using the Mann: Whitney U test.

Risk factors associated with IBD-related disability

In univariate analysis (Table 3), education level (P = .026), azathioprine use (P = .019), any micronutrient deficiency (P = .007), self-reported vitamin D deficiency in the preceding 3 months (P = .011), and iron deficiency (P = .004) were associated with disability status. Azathioprine use was associated with a lower proportion of high disability, whereas any micronutrient deficiency, self-reported vitamin D deficiency in the preceding 3 months, and iron deficiency were associated with a higher proportion of high disability.

All other evaluated sociodemographic, clinical, lifestyle, and treatment-related variables were not significantly associated with disability status in univariate analysis.

Table 3

Univariate analysis of factors associated with IBD-related disability.

VariableLower disability burden (IBD Disk score ≤40), n = 75High disability (IBD Disk >40), n = 104 P-value
Age category 18 and younger 3 (4.0)6 (5.8).061a
19-30 31 (41.3)40 (38.5)
31-50 27 (36.0)51 (49.0)
51 and older 14 (18.7)7 (6.7)
Gender Male 40 (53.3)53 (51.0).754a
Female 35 (46.7)51 (49.0)
Marital status Single 26 (34.7)40 (38.5).391b
Married 47 (62.7)64 (61.5)
Divorced 1 (1.3)0 (0.0)
Widow 1 (1.3)0 (0.0)
Education Primary school 5 (6.7)3 (2.9) .026b
High school 17 (22.7)44 (42.3)
University 48 (64.0)54 (51.9)
Postgraduate 5 (6.7)3 (2.9)
Disease type Crohn’s disease 43 (57.3)63 (60.6).663a
Ulcerative colitis 32 (42.7)41 (39.4)
Disease duration Less than 5 years 21 (28.0)32 (30.8).922a
5-10 years 35 (46.7)47 (45.2)
More than 10 years 19 (25.3)25 (24.0)
Committed to treatment No 7 (9.3)15 (14.4).306a
Yes 68 (90.7)89 (85.6)
Committed to regular follow-ups No 16 (21.3)36 (34.6).053a
Yes 59 (78.7)68 (65.4)
Biologic treatment No 53 (70.7)78 (75.0).518a
Yes 22 (29.3)26 (25.0)
5-aminosalicylates No 48 (64.0)73 (70.2).382a
Yes 27 (36.0)31 (29.8)
Systemic steroids No 70 (93.3)90 (86.5).145a
Yes 5 (6.7)14 (13.5)
Azathioprine No 39 (52.0)72 (69.2) .019a
Yes 36 (48.0)32 (30.8)
Other medications No 64 (85.3)81 (77.9).210a
Yes 11 (14.7)23 (22.1)
Hospitalization No 31 (41.3)33 (31.7).126a
Yes 44 (58.7)71 (68.3)
Had surgery No 62 (82.7)86 (82.7).996a
Yes 13 (17.3)18 (17.3)
Type of surgery † Bowel resection 10 (90.9)9 (56.3).143b
Hemorrhoid/Fistula 0 (0.0)5 (31.3)
Other abdominal surgery (appendix, cholecystectomy) 1 (9.1)2 (12.5)
BMI Underweight 3 (4.0)9 (8.7).357a
Normal 35 (46.7)53 (51.0)
Overweight 19 (25.3)27 (26.0)
Obese 17 (22.7)15 (14.4)
Cigarette smoker No 51 (68.0)62 (59.6).251a
Yes 24 (32.0)42 (40.4)
Smoker (other than cigarettes) Nothing 63 (84.0)86 (82.7).086b
Waterpipe 9 (12.0)18 (17.3)
Vape 3 (4.0)0 (0.0)
Diabetes mellitus No 70 (93.3)102 (98.1).132b
Yes 5 (6.7)2 (1.9)
Hypertension No68 (90.7)101 (97.1).097b
Yes7 (9.3)3 (2.9)
Dyslipidemia No73 (97.3)101 (97.1)1.000b
Yes2 (2.7)3 (2.9)
Behçet’s disease No74 (98.7)103 (99.0)1.000b
Yes1 (1.3)1 (1.0)
Rheumatoid arthritis No73 (97.3)98 (94.2).471b
Yes2 (2.7)6 (5.8)
Psoriasis No72 (96.0)104 (100).072b
Yes3 (4.0)0 (0)
Osteoporosis No74 (98.7)103 (99.0)1.000b
Yes1 (1.3)1 (1.0)
Any deficiencies No54 (72.0)54 (51.9) .007a
Yes21 (28.0)50 (48.1)
Calcium deficiency No72 (96.0)100 (96.2)1.000b
Yes3 (4.0)4 (3.8)
B12 deficiency No70 (93.3)89 (85.6).104a
Yes5 (6.7)15 (14.4)
Vitamin D deficiency No68 (90.7)79 (76.0) .011a
Yes7 (9.3)25 (24.0)
Iron deficiency No64 (85.3)69 (66.3) .004a
Yes11 (14.7)35 (33.7)

Note: Data are presented as n (%) within disability category unless otherwise indicated. Micronutrient deficiencies were self-reported and referred to the preceding 3 months. Values in bold indicate statistically significant associations (P < 0.05).

a

Pearson’s chi-square test.

b

Fisher’s exact test.

†

Type-of-surgery percentages are calculated among participants with available surgery subtype data within each disability category (lower disability burden: n = 11; high disability: n = 16).

Independent predictors of IBD-related disability

In the multivariable binary logistic regression model (Table 4), analysis showed that self-reported vitamin D deficiency in the preceding 3 months remained independently associated with higher odds of high IBD-related disability (aOR 2.93; 95% CI 1.07 to 8.06; P = .037). In contrast, azathioprine use was independently associated with lower odds of high IBD-related disability (aOR 0.421, 95% CI 0.213-0.829, P = .012). No other sociodemographic, clinical, lifestyle, or treatment-related variables included in the model were significantly associated with disability after adjustment.

Table 4

Multivariable logistic regression analysis of factors associated with high IBD-related disability.

VariableCategory aOR 95% CI P-value
Age category 18 and youngerReference
19-300.6770.134-3.429.637
31-500.9370.185-4.748.938
51 and older0.2130.034-1.327.097
Education Primary schoolReference
High school2.9490.569-15.277.198
University1.2100.243-6.016.816
Postgraduate0.9830.102-9.446.988
Vitamin D deficiency NoReference
Yes2.9321.066-8.060 .037
Azathioprine NoReference
Yes0.4210.213-0.829 .012
Gender MaleReference
Female1.0380.497-2.168.922
Smoker NoReference
Yes0.9910.454-2.165.983
Iron deficiency NoReference
Yes2.0560.867-4.878.102

Note: Reference category shown for each variable. Vitamin D and iron deficiencies were self-reported and referred to the preceding 3 months. Values in bold indicate statistically significant associations (P < 0.05).

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval.

Correlation analysis

A Spearman’s correlation analysis (Table 5) was performed to assess the relationship between IBD-related disability scores and continuous variables. Among patients with CD, the number of cigarettes smoked per day showed a weak but statistically significant positive correlation with IBD Disk scores (ρ = 0.229; P = .018). There were no significant correlations between IBD-related disability and age, disease duration, BMI, or years of marriage.

Table 5

Spearman correlation of total IBD Disk score with selected continuous variables overall and by disease type.

VariableOverall, ρ P-valueCD, ρ P-valueUC, ρ P-value
Age −0.026.7330.000.999−0.060.615
Disease duration (years) −0.082.275−0.185.0580.064.592
BMI −0.043.568−0.096.3310.085.474
Cigarette number per day 0.112.134 0.229 .018 −0.113.340
Years of marriage −0.093.330−0.034.810−0.100.455

Note: Analyses were performed using available data within each group. Values in bold indicate statistically significant associations (P < 0.05).

Abbreviation: ρ, Spearman’s rank correlation coefficient.

Exploratory subgroup analysis

Exploratory subgroup analysis was performed according to biologic therapy status and prior surgical history. Mean total IBD Disk scores were similar between patients receiving biologic therapy and those not receiving biologic therapy (44.15 ± 22.86 vs 45.74 ± 23.40, P = .665). Likewise, mean total IBD Disk scores were similar between patients with prior surgical history and those without prior surgery (47.45 ± 22.74 vs 44.86 ± 23.35, P = .512). No significant differences were observed across individual IBD Disk domain scores in either comparison (Table S1).

Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Conclusion

This study revealed that the prevalence of IBD disability in Palestine was 58.1%, with joint pain being the domain with the highest scores. This highlights the substantial disability burden observed among Palestinian patients with IBD. Azathioprine use was associated with lower disability scores, whereas self-reported vitamin D deficiency in the preceding 3 months was associated with higher disability. In addition, cigarettes smoked per day showed a weak positive correlation with IBD Disk scores among patients with CD, whereas smoking status was not independently associated with high disability in the multivariable model.

These findings should be interpreted cautiously given the cross-sectional design, self-reported exposures, and absence of objective disease activity measures. All in all, implementing routine disability assessment using the IBD Disk may support early identification of high-risk patients and guide more targeted clinical interventions to improve outcomes for individuals living with IBD.

Source: Conclusion
Authors’ abstract

Abstract

Background

Inflammatory bowel disease (IBD) can substantially impair daily functioning, yet disability prevalence and determinants remain underexplored in Palestine. This study aimed to assess the prevalence of IBD-related disability using the IBD Disk tool and to identify risk factors associated with high disability among Palestinian patients.

Methods

A cross-sectional study was conducted among patients with a confirmed diagnosis of Crohn’s disease (CD) or ulcerative colitis for at least six months. Participants completed an Arabic translation of the IBD Disk prepared through forward-backward translation. Demographic, clinical, and lifestyle data were collected. Disability was defined as an IBD Disk total score >40. Logistic regression was used to identify factors independently associated with disability.

Results

A total of 179 patients (59.2% CD, mean age 33.68 ± 12.27 years) participated. The prevalence of IBD-related disability was 58.1%, with a mean total IBD Disk score of 45.31 ± 23.20. Joint pain was the highest-scoring domain (6.06 ± 3.32), while sexual function scored lowest (2.46 ± 2.43). While azathioprine use (adjusted odds ratio [aOR] 0.421, 95% confidence interval [CI] 0.213-0.829, P = .012) was associated with lower disability, self-reported vitamin D deficiency in the preceding 3 months was associated with higher disability (aOR 2.932, 95% CI 1.066-8.060, P = .03).

Among patients with CD, cigarettes smoked per day showed a weak positive correlation with IBD Disk scores.

Conclusions

High disability was common among Palestinian patients with IBD. Self-reported vitamin D deficiency in the preceding 3 months was associated with higher odds of high disability, whereas azathioprine use was associated with lower odds. Cigarettes smoked per day showed a weak positive correlation with disability scores among patients with CD, but smoking status was not independently associated with high disability.

Read the full paper

Introduction

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic, relapsing-remitting disease characterized by alternating active and remission episodes of intestinal inflammation.1 A complex interplay of host genetic, microbial, and environmental variables contributes to its pathogenesis. However, there are still unanswered questions regarding the etiology and behavior of the disease.2 Globally, the burden of IBD is a significant public health challenge. This burden is mainly due to the increased prevalence, especially in newly industrialized areas in South America, Asia, and Africa, which places an increasing social and financial strain on society, governments, and healthcare systems.3 to 5 Compared with the general population, patients with IBD experience reduced quality of life and higher rates of disability.6 to 8

Even though IBD is linked to substantial morbidity and disability, which at times necessitates hospitalization and surgery, physicians frequently underestimate the impact of this disease on their patients’ lives.9,10 IBD-related disability occurs due to several factors, with the nature of it being an incurable relapsing-remitting disease with heterogeneous clinical presentation being a major one. Another factor is its association with extraintestinal systemic symptoms such as fatigue and occasionally fever besides cutaneous, hepatobiliary, rheumatological, and ophthalmological manifestations.11 to 13 Physical, psychological, familial, and social aspects of this illness also play a role in disability.14,15

In recent years, preventing disability has garnered increasing attention as there has been a significant change in the treatment paradigm from symptom control to complete disease control (clinical and endoscopic relief). The end goal of such change has been to stop the disease’s progression and preventing intestinal damage and subsequently the ensuing disability.16 The updated Selecting Therapeutic Targets in Inflammatory Bowel Disease further highlights that in addition to clinical remission and endoscopic healing, major long-term goals focus on the absence of disability, restoration of quality of life, and normal growth in children.17

Adopting the World Health Organization (WHO) definition, IBD-related disability includes restrictions on one’s ability to pursue education and employment, exclusion from social and economic activities, and impairments of one’s physical and psychological functioning.18 In an effort to measure disability, the IBD Disability Index (IBD-DI) was developed in collaboration with the WHO.19 It allows patients to be followed to evaluate the effects of treatment plans and pathways on the progression of illnesses, the degree of disability, and the overall impact of the condition.10 While the IBD-DI is a useful tool for assessing disability, its length often limits its use in busy clinical settings.

Recently, a shortened self-administered tool derived from the IBD-DI, called the IBD Disk, was developed. This tool was created for routine clinical assessment as a more convenient way of capturing disability caused by IBD.20 Despite the increasing burden of IBD in many regions, including the Middle East, IBD-related disability remains an understudied issue. To our knowledge, there has been no study assessing IBD disability using the IBD Disk in Palestine. Therefore, this study aimed to determine the prevalence of IBD-related disability among Palestinian patients using the IBD Disk and to identify the risk factors associated with higher disability.

Materials and methods

Study design and setting

A cross-sectional study was conducted in the Northern West Bank, Palestine from April 2025 to September 2025. The study assessed IBD-related disability and associated risk factors among patients with IBD attending follow-up visits at multiple general outpatient gastroenterology clinics across the Northern West Bank. Recruitment was clinic-based and involved patients receiving follow-up care in general gastroenterology practice rather than in specialized IBD referral clinics or through a centralized registry or database.

Participants and sampling

A convenience sampling method was employed, where all those attending outpatient follow-up visits who met the eligibility criteria were invited to participate in the study. Participants included in the study were those with a confirmed diagnosis of CD or UC established by a gastroenterologist based on endoscopic and histologic evaluation. Inclusion criteria also included disease duration ≥6 months. All ages were included provided that they were able to independently complete the Arabic questionnaire. Patients who had a diagnosis other than IBD, filled incomplete questionnaires, or were unable to complete the questionnaire due to cognitive or language limitations, were excluded from the study.

Because recruitment was based on convenience sampling during clinic attendance and the number of eligible patients approached was not systematically recorded, a formal survey response rate could not be calculated. Recruitment was limited to patients attending outpatient follow-up visits during the study period.

The sample size for this study was calculated using the Raosoft sample size calculator. Based on an estimated population of 367 patients, assuming a 95% confidence level, a 5% margin of error, and an expected outcome prevalence of 19% derived from a Saudi IBD Disk-based study, the minimum required sample size was 145 patients.21,22 The final sample size collected was 179, exceeding the minimum required sample size.

Data collection and study variables

Data were collected using a structured Arabic questionnaire distributed as a Google Form. Questionnaires were completed by participants during clinic visits with trained researchers available to clarify any items. All variables were obtained through patient self-report, including height and weight, from which body mass index (BMI) was calculated. The questionnaire was made up of several sections covering sociodemographic characteristics, lifestyle factors, anthropometric information, disease-related variables, treatment history, comorbidities, micronutrient deficiencies, and the IBD Disk instrument. All reported clinical characteristics, comorbidities, treatment exposures, smoking variables, and hospitalization or surgical history were based on participant self-report and were not independently verified using medical records, laboratory data, or endoscopic/biochemical assessments.

Self-reported micronutrient deficiencies referred to the preceding 3 months. Current supplement and medication use was recorded separately. Accordingly, objective disease activity indices such as clinical scores, inflammatory biomarkers, or endoscopic severity measures were not available for analysis.

Collected variables included demographic and clinical characteristics including age, gender, marital status, education level, BMI, smoking status (cigarettes), number of cigarettes per day, waterpipe/vape use, disease type (CD vs UC), disease duration, history of surgery, history of hospitalization, adherence to treatment, adherence to follow-up visits, use of 5-aminosalicylates (5-ASA), use of azathioprine, use of biologic therapy, use of systemic corticosteroids, use of other medications, presence of other chronic diseases (diabetes mellitus, hypertension, dyslipidemia, Behçet’s disease, rheumatoid arthritis, psoriasis, osteoporosis, and others), and presence of any self-reported nutrient deficiency in the preceding 3 months (vitamin D deficiency, iron deficiency, vitamin B12 deficiency, calcium deficiency, and other deficiencies).

The primary outcome was IBD-related disability, measured using the total IBD Disk score (0 to 100). For analytic purposes, participants were categorized as having high disability (IBD Disk score >40) or lower disability burden (IBD Disk score ≤40).

IBD Disk instrument

The IBD Disk is made up of 10 domains. The components include abdominal pain, regulating defecation, interpersonal interactions, education and work, sleep, energy, emotions, body image, sexual functions, and joint pain. Sub-scores for each of the ten components in the IBD Disk questionnaire provide information regarding the patient’s impairment, systemic symptoms, manifestations, and overall effects on social life. Responses are provided on a scale ranging from 0 to 10 (0 = no burden; 10 = maximal burden). The total score was out of 100; the best score is 0, while the worst score is 100.

A cutoff score of >40 was used to determine high disability as it has been linked to a high daily-life burden from IBD.23

The original English IBD Disk questionnaire was translated into Arabic using a forward-backward translation process conducted by independent bilingual translators. The final translated version was then reviewed and approved by a gastroenterologist to confirm its clinical relevance and conceptual accuracy. Prior to data collection, the translated questionnaire was pilot tested with 10 patients with IBD to assess item clarity, comprehension, wording, and feasibility of completion in the target patient population. A small sample of 10 patients with IBD was considered appropriate for this preliminary linguistic and face-validity pretest because the aim was to identify major comprehension or wording problems before full data collection, rather than to perform formal psychometric validation.

As no major comprehension difficulties were identified and only minor wording revisions were required, the pilot sample was not expanded before full recruitment. Internal consistency was subsequently assessed in the full study sample using Cronbach’s alpha, which yielded a value of 0.89.

Statistical analysis

For data analysis, we used IBM Statistical Package for the Social Sciences. Descriptive statistics were calculated and presented as frequencies and percentages, while continuous variables were summarized as means ± standard deviations. Normality of continuous variables was assessed using the Shapiro: Wilk test. Because total IBD Disk score and individual domain scores were not normally distributed, comparisons between patients with CD and UC were performed using the Mann: Whitney U test. Pearson’s chi-square test and Fisher’s exact test (when expected cell counts were less than 5) were used to determine the associations between various predictor variables and outcome (high disability vs lower disability burden).

Independent predictors of disability were identified using multivariable binary logistic regression with results reported as adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Variables with a P-value < .20 in the univariate analysis, as well as clinically relevant factors identified, were entered into the multivariable binary logistic regression model. Spearman’s rank correlation was used to assess associations between the continuous IBD Disk score and continuous variables. Exploratory subgroup analysis was additionally performed by stratifying patients according to biologic therapy status and prior surgical history.

Differences in total IBD Disk score and individual domains were also assessed using the Mann: Whitney U test. A P-value less than .05 was considered significant.

Ethical considerations

IRB (Institutional Review Board) approval was obtained prior to questionnaire distribution [Reference: Med. March. 2025/36]. Written informed consent was obtained from all adult participants prior to participation. For participants aged below 18 years, written informed consent was obtained from a parent or legal guardian, and participant assent was obtained when applicable. Confidentiality, anonymity, and voluntary participation were ensured.

Results

Characteristics of the patients

A total of 179 patients with IBD were included in this study. The mean age was 33.68 ± 12.27 and 93 (52.0%) were male. Most patients, 111 (62.0%) were married and 102 (57.0%) had university degrees. As for disease distribution, the majority of patients, 106 (59.2%) had CD, while 73 (40.8%) were diagnosed with UC. The mean duration of the disease was 8.43 ± 6.68 years.

In terms of lifestyle factors, 66 (36.9%) were cigarette smokers with a mean of 4.29 ± 10.17 cigarettes per day. Nearly half of the patients, 88 (49.4%) had a normal BMI while 78 (43.8%) were overweight or obese. The mean BMI was 26.08 ± 4.73 kg/m2. Comorbidities reported by patients were relatively infrequent. Hypertension 10 (5.6%) and rheumatoid arthritis 8 (4.5%) were the most common. Other comorbidities included diabetes mellitus 7 (3.9%), dyslipidemia 5 (2.8%), psoriasis 3 (1.7%), osteoporosis 2 (1.1%), and Behçet’s disease 2 (1.1%).

Regarding treatment, 58 (32.4%) were using 5-aminosalicylates, 68 (38.0%) were using azathioprine, 48 (26.8%) were on biologic treatment, and 19 (10.6%) were taking systemic corticosteroids. Self-reported medication and follow-up adherence was high, with (87.7%) reporting commitment to treatment and 127 (70.9%) committed to regular follow-ups.

More than half of the patients, 115 (64.2%) had a history of IBD-related hospitalization. A total of 31 (17.3%) patients reported having IBD-related surgery, with 19 (61.3%) of them undergoing bowel resections. More details are seen in Table 1.

Table 1

Demographic and clinical characteristics of the study participants (N = 179).

VariableTotal: n (%) or mean ± SD
Age, years (mean ± SD) 33.68 ± 12.27
Age groups
  18 and younger 9 (5.0)
  19-30 71 (39.7)
  31-50 78 (43.6)
  51 and older 21 (11.7)
Gender
  Male 93 (52.0)
  Female 86 (48.0)
Marital status
  Single 66 (36.9)
  Married 111 (62.0)
  Divorced 1 (0.6)
  Widow 1 (0.6)
Years of marriage, years (mean ± SD) 15.33 ± 11.42
Education
  Primary school 8 (4.5)
  High school 61 (34.1)
  University 102 (57.0)
  Postgraduate 8 (4.5)
Disease type
  Crohn’s disease 106 (59.2)
  Ulcerative colitis 73 (40.8)
Disease duration, years (mean ± SD) 8.43 ± 6.68
Disease duration
  Less than 5 years 53 (29.6)
  5-10 years 82 (45.8)
  more than 10 years 44 (24.6)
Committed to treatment
  Yes 157 (87.7)
  No 22 (12.3)
Committed to regular follow-ups
  Yes 127 (70.9)
  No 52 (29.1)
Reason for not being committed to doctor visit
  Stable 26 (14.5)
  Medications not available 1 (0.6)
  Difficult transportation 9 (5)
  Not committed 6 (3.4)
  Financial 7 (3.9)
Medication
  5-aminosalicylates 58 (32.4)
  Azathioprine 68 (38.0)
  Biologic 48 (26.8)
  Systemic corticosteroids 19 (10.6)
  Other medications 34 (19.6)
Hospitalization
  No 64 (35.7)
  Yes 115 (64.2)
Had surgery
  No 148 (82.7)
  Yes 31 (17.3)
Type of surgery
  Bowel resection 19 (10.6)
  Hemorrhoid/Fistula 5 (2.8)
  Other abdominal surgery (appendix, cholecystectomy) 7 (3.9)
Other chronic diseases
  Diabetes Mellitus 7 (3.9)
  Hypertension 10 (5.6)
  Dyslipidemia 5 (2.8)
  Behçet’s disease 2 (1.1)
  Rheumatoid arthritis 8 (4.5)
  Psoriasis 3 (1.7)
  Osteoporosis 2 (1.1)
  Others 15 (8.4)
BMI
  Underweight 12 (6.7)
  Normal 88 (49.4)
  Overweight 46 (25.8)
  Obese 32 (18)
Cigarette smoker
  No 113 (63.1)
  Yes 66 (36.9)
Cigarettes per day, number/day (mean ± SD) 4.29 ± 10.17
Smoker (other than cigarette)
  Nothing 149 (83.0)
  Waterpipe 27 (15.1)
  Vape 3 (1.7)

Abbreviations: BMI, body mass index; SD, standard deviation.

IBD-related disability scores

The mean total IBD Disk score in this study was 45.31 ± 23.2. Using a cutoff value of more than 40 to define high disability, 104 (58.1%) patients were classified as having high disability, whereas 75 (41.9%) were classified as having lower disability burden (IBD Disk score ≤40). The highest mean scores observed across the 10 IBD Disk domains were joint pain with a mean of 6.06 ± 3.32, tiredness/lack of energy (5.70 ± 3.33), emotional wellbeing (5.41 ± 3.49), and sleep disturbances (5.31 ± 3.46).

The lowest score was observed in the sexual domain (2.46 ± 2.43). A visual representation of the overall disability profile is provided in Figure 1, which demonstrates the distribution of mean domain scores across the IBD Disk. Mean total IBD Disk scores were similar between patients with CD and those with UC (45.92 ± 23.07 vs 44.42 ± 23.52, P = .564). No significant differences were observed between disease types across any individual IBD Disk domain scores (Table 2).

Figure 1

Radar plot showing mean IBD Disk domain scores among Palestinian patients with inflammatory bowel disease. Higher scores indicate greater impairment in the corresponding domain (scale 0-10). IBD, inflammatory bowel disease.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 2

IBD Disk total and domain scores overall and by disease type.

VariableTotal, mean ± SDUC, mean ± SDCD, mean ± SD P-value
Total IBD Disk score 45.31 ± 23.2044.42 ± 23.5245.92 ± 23.07.564
Abdominal pain 4.99 ± 3.164.52 ± 2.955.31 ± 3.26.086
Regulating defecation 3.55 ± 3.053.51 ± 3.073.58 ± 3.06.736
Interpersonal interactions 3.56 ± 3.173.93 ± 3.273.30 ± 3.09.172
Education and work 4.18 ± 3.434.15 ± 3.334.21 ± 3.51.983
Sleep 5.31 ± 3.464.92 ± 3.385.58 ± 3.50.200
Energy 5.70 ± 3.335.45 ± 3.125.88 ± 3.47.321
Emotions 5.41 ± 3.495.47 ± 3.125.37 ± 3.52.770
Body image 4.08 ± 3.254.04 ± 3.124.11 ± 3.35.982
Sexual functions 2.46 ± 2.432.42 ± 2.252.49 ± 2.55.775
Joint pain 6.06 ± 3.326.01 ± 3.426.09 ± 3.26.863

Note: Data are presented as mean ± SD. P-values represent comparisons between Crohn’s disease and ulcerative colitis using the Mann: Whitney U test.

Risk factors associated with IBD-related disability

In univariate analysis (Table 3), education level (P = .026), azathioprine use (P = .019), any micronutrient deficiency (P = .007), self-reported vitamin D deficiency in the preceding 3 months (P = .011), and iron deficiency (P = .004) were associated with disability status. Azathioprine use was associated with a lower proportion of high disability, whereas any micronutrient deficiency, self-reported vitamin D deficiency in the preceding 3 months, and iron deficiency were associated with a higher proportion of high disability.

All other evaluated sociodemographic, clinical, lifestyle, and treatment-related variables were not significantly associated with disability status in univariate analysis.

Table 3

Univariate analysis of factors associated with IBD-related disability.

VariableLower disability burden (IBD Disk score ≤40), n = 75High disability (IBD Disk >40), n = 104 P-value
Age category 18 and younger 3 (4.0)6 (5.8).061a
19-30 31 (41.3)40 (38.5)
31-50 27 (36.0)51 (49.0)
51 and older 14 (18.7)7 (6.7)
Gender Male 40 (53.3)53 (51.0).754a
Female 35 (46.7)51 (49.0)
Marital status Single 26 (34.7)40 (38.5).391b
Married 47 (62.7)64 (61.5)
Divorced 1 (1.3)0 (0.0)
Widow 1 (1.3)0 (0.0)
Education Primary school 5 (6.7)3 (2.9) .026b
High school 17 (22.7)44 (42.3)
University 48 (64.0)54 (51.9)
Postgraduate 5 (6.7)3 (2.9)
Disease type Crohn’s disease 43 (57.3)63 (60.6).663a
Ulcerative colitis 32 (42.7)41 (39.4)
Disease duration Less than 5 years 21 (28.0)32 (30.8).922a
5-10 years 35 (46.7)47 (45.2)
More than 10 years 19 (25.3)25 (24.0)
Committed to treatment No 7 (9.3)15 (14.4).306a
Yes 68 (90.7)89 (85.6)
Committed to regular follow-ups No 16 (21.3)36 (34.6).053a
Yes 59 (78.7)68 (65.4)
Biologic treatment No 53 (70.7)78 (75.0).518a
Yes 22 (29.3)26 (25.0)
5-aminosalicylates No 48 (64.0)73 (70.2).382a
Yes 27 (36.0)31 (29.8)
Systemic steroids No 70 (93.3)90 (86.5).145a
Yes 5 (6.7)14 (13.5)
Azathioprine No 39 (52.0)72 (69.2) .019a
Yes 36 (48.0)32 (30.8)
Other medications No 64 (85.3)81 (77.9).210a
Yes 11 (14.7)23 (22.1)
Hospitalization No 31 (41.3)33 (31.7).126a
Yes 44 (58.7)71 (68.3)
Had surgery No 62 (82.7)86 (82.7).996a
Yes 13 (17.3)18 (17.3)
Type of surgery † Bowel resection 10 (90.9)9 (56.3).143b
Hemorrhoid/Fistula 0 (0.0)5 (31.3)
Other abdominal surgery (appendix, cholecystectomy) 1 (9.1)2 (12.5)
BMI Underweight 3 (4.0)9 (8.7).357a
Normal 35 (46.7)53 (51.0)
Overweight 19 (25.3)27 (26.0)
Obese 17 (22.7)15 (14.4)
Cigarette smoker No 51 (68.0)62 (59.6).251a
Yes 24 (32.0)42 (40.4)
Smoker (other than cigarettes) Nothing 63 (84.0)86 (82.7).086b
Waterpipe 9 (12.0)18 (17.3)
Vape 3 (4.0)0 (0.0)
Diabetes mellitus No 70 (93.3)102 (98.1).132b
Yes 5 (6.7)2 (1.9)
Hypertension No68 (90.7)101 (97.1).097b
Yes7 (9.3)3 (2.9)
Dyslipidemia No73 (97.3)101 (97.1)1.000b
Yes2 (2.7)3 (2.9)
Behçet’s disease No74 (98.7)103 (99.0)1.000b
Yes1 (1.3)1 (1.0)
Rheumatoid arthritis No73 (97.3)98 (94.2).471b
Yes2 (2.7)6 (5.8)
Psoriasis No72 (96.0)104 (100).072b
Yes3 (4.0)0 (0)
Osteoporosis No74 (98.7)103 (99.0)1.000b
Yes1 (1.3)1 (1.0)
Any deficiencies No54 (72.0)54 (51.9) .007a
Yes21 (28.0)50 (48.1)
Calcium deficiency No72 (96.0)100 (96.2)1.000b
Yes3 (4.0)4 (3.8)
B12 deficiency No70 (93.3)89 (85.6).104a
Yes5 (6.7)15 (14.4)
Vitamin D deficiency No68 (90.7)79 (76.0) .011a
Yes7 (9.3)25 (24.0)
Iron deficiency No64 (85.3)69 (66.3) .004a
Yes11 (14.7)35 (33.7)

Note: Data are presented as n (%) within disability category unless otherwise indicated. Micronutrient deficiencies were self-reported and referred to the preceding 3 months. Values in bold indicate statistically significant associations (P < 0.05).

a

Pearson’s chi-square test.

b

Fisher’s exact test.

†

Type-of-surgery percentages are calculated among participants with available surgery subtype data within each disability category (lower disability burden: n = 11; high disability: n = 16).

Independent predictors of IBD-related disability

In the multivariable binary logistic regression model (Table 4), analysis showed that self-reported vitamin D deficiency in the preceding 3 months remained independently associated with higher odds of high IBD-related disability (aOR 2.93; 95% CI 1.07 to 8.06; P = .037). In contrast, azathioprine use was independently associated with lower odds of high IBD-related disability (aOR 0.421, 95% CI 0.213-0.829, P = .012). No other sociodemographic, clinical, lifestyle, or treatment-related variables included in the model were significantly associated with disability after adjustment.

Table 4

Multivariable logistic regression analysis of factors associated with high IBD-related disability.

VariableCategory aOR 95% CI P-value
Age category 18 and youngerReference
19-300.6770.134-3.429.637
31-500.9370.185-4.748.938
51 and older0.2130.034-1.327.097
Education Primary schoolReference
High school2.9490.569-15.277.198
University1.2100.243-6.016.816
Postgraduate0.9830.102-9.446.988
Vitamin D deficiency NoReference
Yes2.9321.066-8.060 .037
Azathioprine NoReference
Yes0.4210.213-0.829 .012
Gender MaleReference
Female1.0380.497-2.168.922
Smoker NoReference
Yes0.9910.454-2.165.983
Iron deficiency NoReference
Yes2.0560.867-4.878.102

Note: Reference category shown for each variable. Vitamin D and iron deficiencies were self-reported and referred to the preceding 3 months. Values in bold indicate statistically significant associations (P < 0.05).

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval.

Correlation analysis

A Spearman’s correlation analysis (Table 5) was performed to assess the relationship between IBD-related disability scores and continuous variables. Among patients with CD, the number of cigarettes smoked per day showed a weak but statistically significant positive correlation with IBD Disk scores (ρ = 0.229; P = .018). There were no significant correlations between IBD-related disability and age, disease duration, BMI, or years of marriage.

Table 5

Spearman correlation of total IBD Disk score with selected continuous variables overall and by disease type.

VariableOverall, ρ P-valueCD, ρ P-valueUC, ρ P-value
Age −0.026.7330.000.999−0.060.615
Disease duration (years) −0.082.275−0.185.0580.064.592
BMI −0.043.568−0.096.3310.085.474
Cigarette number per day 0.112.134 0.229 .018 −0.113.340
Years of marriage −0.093.330−0.034.810−0.100.455

Note: Analyses were performed using available data within each group. Values in bold indicate statistically significant associations (P < 0.05).

Abbreviation: ρ, Spearman’s rank correlation coefficient.

Exploratory subgroup analysis

Exploratory subgroup analysis was performed according to biologic therapy status and prior surgical history. Mean total IBD Disk scores were similar between patients receiving biologic therapy and those not receiving biologic therapy (44.15 ± 22.86 vs 45.74 ± 23.40, P = .665). Likewise, mean total IBD Disk scores were similar between patients with prior surgical history and those without prior surgery (47.45 ± 22.74 vs 44.86 ± 23.35, P = .512). No significant differences were observed across individual IBD Disk domain scores in either comparison (Table S1).

Discussion

This cross-sectional study assessed disability among Palestinian patients with IBD using the IBD Disk and found that more than half of the cohort experienced high levels of disability. The most impaired domains observed were joint pain, tiredness, emotional difficulties, and sleep disturbance. Cigarettes smoked per day showed a weak positive correlation with IBD Disk scores among patients with CD. In adjusted analysis, self-reported vitamin D deficiency in the preceding 3 months was associated with higher odds of high disability, whereas azathioprine use was associated with lower odds.

Given the cross-sectional design, reliance on self-reported clinical exposures, and absence of objective disease activity measures, these associations should be interpreted as associative rather than causal and may partly reflect unmeasured differences in underlying disease activity or severity.

The disability level observed in this study exceeds those reported in several regional and international studies suggesting a comparatively greater functional burden. A Western study measuring IBD-related disability reported a mean score of 39.3 (±23.0), while another Saudi-based study reported a mean total IBD score of 20.70 (±18.69) and a 19% prevalence of IBD-related disability. Disability levels in this study were similar between CD and UC patients, mirroring findings in the Saudi-based and Western studies showing comparable disability levels. This suggests that disease type isn’t strictly reflective of disability and functional impairment.

Higher scores in the joint pain domain were also reported in our study compared to those in the Western and Saudi Arabian studies, while the sexual function domain was consistently reported as the lowest across the studies.22,23 These differences may reflect variations in disease perception, access to specialized care, treatment pathways, and burden of extraintestinal manifestations. They may also reflect unmeasured clinical heterogeneity, including disease extent, which was not available in our dataset. The higher joint pain scores observed in our cohort may reflect an underrecognized burden of musculoskeletal extraintestinal manifestations and possible gaps in rheumatologic assessment and follow-up among patients with IBD.

Since extraintestinal manifestations were not comprehensively characterized in our dataset, their specific contribution to the overall disability profile could not be fully determined. The sexual function domain being consistently reported as the lowest domain in literature is likely influenced by cultural norms and stigma surrounding the topic resulting in reluctance of patients to disclose sensitive information.

Azathioprine use in this study was associated with a lower burden of IBD-related disability. This observation aligns with previous work showing that thiopurines can support sustained remission and enhance patient-reported quality of life in appropriately selected individuals.24 A recent cohort noted that patients maintained on azathioprine often report better health-related quality of life outcomes compared with those managed with alternative therapies.25 However, this relationship must be interpreted cautiously. In clinical practice, patients who continue azathioprine typically represent a group with relatively stable or less aggressive disease, whereas escalation to biologic therapy usually occurs in the setting of more severe, refractory, or complicated IBD.26 to 28 This therapeutic “channeling” may partly explain the lower disability scores observed in azathioprine users, reflecting milder underlying disease rather than a direct comparative advantage of thiopurines over biologics.

Even so, the observed association may reflect the better day-to-day functioning seen among patients whose disease is adequately controlled on a well-tolerated immunomodulator, although this interpretation remains speculative in the absence of objective disease activity measures.

The proportion of patients receiving biologic therapy in our cohort was relatively low (26.8%). While the relatively low proportion of patients receiving biologic therapy in our cohort may reflect a milder disease profile in some patients, it may also be related to local prescribing patterns, delayed treatment escalation, or limitations in treatment access. However, the present study was not designed to distinguish between these possibilities and detailed data on duration of treatment, prior treatment escalation, and combination therapy were not available, which further limits interpretation of this finding.

Additionally, exploratory subgroup analyses did not demonstrate significant differences in total or domain-specific IBD Disk scores according to biologic therapy status. However, this finding should be interpreted cautiously, as biologic use alone may not adequately reflect disease severity, particularly in the absence of data on disease extent and activity.

Self-reported vitamin D deficiency in the preceding 3 months was independently associated with higher odds of high IBD-related disability in our analysis. This finding is consistent with previous literature linking low vitamin D status with higher disease activity and poorer health-related quality of life in IBD.29,30 Experimental and clinical data indicate that vitamin D supports mucosal healing through antimicrobial activity, modulation of intestinal inflammation, and enhancement of epithelial barrier integrity, providing a biological rationale for its potential contribution to disease control.31 Moreover, a recent meta-analysis of randomized trials reported that vitamin D supplementation as an adjuvant significantly reduced the rate of relapse in IBD by 64%, reinforcing the potential clinical relevance of maintaining adequate levels.32 Vitamin D deficiency in IBD patients has been linked to several clinical risk factors, including intestinal resection, stricture complications, early corticosteroid requirement, and extensive colonic involvement in UC.33 However, this association should be interpreted cautiously because vitamin D deficiency was self-reported rather than laboratory confirmed, which introduces the possibility of misclassification bias.

The questionnaire captured self-reported vitamin D deficiency within the preceding 3 months, and current supplement and medication use was recorded separately. However, no data were available regarding laboratory values, deficiency severity, or whether the reported deficiency represented a prior diagnosis, a persistent deficiency, or a treated deficiency. It is therefore not possible to determine whether self-reported recent vitamin D deficiency itself was associated with greater disability, or whether it served as a marker of more active disease, poorer general health, extraintestinal burden, or other unmeasured factors.

This distinction is particularly important because objective disease activity measures were not available in the present study. Future studies incorporating objective laboratory and disease activity data are needed to better clarify this relationship.

The weak positive correlation observed between cigarette number per day and IBD-related disability among patients with CD is in line with prior evidence. One study demonstrated that smoking not only contributes to the development of CD, but is also associated with poorer prognosis, reduced treatment response, and increased complications.34 Another study encourages the immediate cessation of smoking in CD patients, due to the worse outcomes smoking CD patients had, even with treatment, whether using biologics or surgery.35 However, in our study, smoking was only weakly correlated with disability scores, and no objective disease activity measures were available; therefore, the relationship should be interpreted cautiously.

Strengths and limitations

This study has several strengths. It is the first study in Palestine that addresses and measures disability in IBD patients using the IBD-Disk, providing valuable insight from an understudied population. The sample size obtained, exceeding the minimum required sample size, enhances the robustness of the analysis. Additionally, the Arabic version of the IBD Disk used in this study underwent a structured translation and back-translation process, and demonstrated strong internal consistency (Cronbach’s α = 0.89), supporting its reliability for use in this context.

Despite these strengths, this study has several limitations. First, the cross-sectional design does not allow causal inference, and the observed relationships should be interpreted as associations instead. Second, the study relied largely on self-reported data, including treatment history, comorbidities, smoking exposure, hospitalization, surgery, and micronutrient deficiencies, which introduces potential recall and misclassification bias. In particular, vitamin D deficiency was assessed by self-report for the preceding 3 months rather than by laboratory confirmation, and no data were available regarding laboratory values, deficiency severity, or whether the reported deficiency represented prior, persistent, or treated deficiency.

Third, we did not collect objective measures of disease activity such as clinical indices, inflammatory biomarkers, or endoscopic assessments. Accordingly, it was not possible to determine whether the observed disability primarily reflected active intestinal disease, extraintestinal manifestations, psychosocial factors, or a combination of these influences. Because disease activity is strongly associated with disability in IBD, the absence of objective activity data limits interpretation of the observed associations. Fourth, several potentially important predictors of disability were not systematically assessed or comprehensively characterized, including extraintestinal manifestations, depression, anxiety, socioeconomic status, and healthcare-access factors.

These variables may influence disability independently of intestinal disease activity and may have contributed to the burden observed in this cohort. Fifth, we did not collect detailed disease-phenotype data such as disease extent or distribution, which may influence disability burden and could have differed between patient groups. Sixth, detailed treatment characterization, including duration of biologic exposure and combination therapy, was not available. We were also unable to determine whether the relatively low biologic-use rate reflected disease severity, access limitations, or local treatment practices.

Finally, participants were recruited from general outpatient gastroenterology clinics in the Northern West Bank using convenience sampling, which may have introduced selection bias. Although these were general clinics rather than specialized IBD referral clinics, the sample may still overrepresent patients who are more engaged with follow-up care and underrepresent those who do not attend regularly. As a result, the severity profile and disability burden observed in this study may not fully reflect all patients with IBD in the community. This also limits the generalizability of the findings to patients outside this clinic-attending population and to other regions.

Implications and recommendations

The findings of this study highlight the importance of integrating disability assessment into routine IBD care. Using the IBD Disk offers a rapid evaluation targeting several dimensions. This can help physicians identify patients with substantial functional burden regardless of traditional markers which may appear stable. The IBD Disk may help identify patients reporting substantial functional burden in routine care. Future longitudinal studies should incorporate objective disease activity measures, disease extent, extraintestinal manifestations, depression and anxiety, healthcare-access factors, and detailed biologic exposure data, including exposure duration, to better define independent predictors of disability.

Conclusion

This study revealed that the prevalence of IBD disability in Palestine was 58.1%, with joint pain being the domain with the highest scores. This highlights the substantial disability burden observed among Palestinian patients with IBD. Azathioprine use was associated with lower disability scores, whereas self-reported vitamin D deficiency in the preceding 3 months was associated with higher disability. In addition, cigarettes smoked per day showed a weak positive correlation with IBD Disk scores among patients with CD, whereas smoking status was not independently associated with high disability in the multivariable model.

These findings should be interpreted cautiously given the cross-sectional design, self-reported exposures, and absence of objective disease activity measures. All in all, implementing routine disability assessment using the IBD Disk may support early identification of high-risk patients and guide more targeted clinical interventions to improve outcomes for individuals living with IBD.

Supplementary Material

otag079_Supplementary_Data
Supplement file at the original source: open the original paper. This file is not included in this text import.

Acknowledgements

The authors used ChatGPT (OpenAI) solely to assist with language refinement of the manuscript. All intellectual content, data interpretation, and conclusions were generated and verified by the authors.

Author contributions

A.Q. and Q.A. contributed to the study conception and design, methodology development, and literature review. A.Q., R.K., K.K., and S.S. contributed to data collection. A.Q., R.K., K.K., and D.Q. contributed to data analysis and interpretation of the findings. A.Q., R.K., K.K., S.S., and D.Q. contributed to drafting, critical revision, and preparation of the final manuscript. Q.A. provided supervision, critical review, and substantial editing of the manuscript. All authors approved the final submitted version and agree to be accountable for the work.

Supplementary material

Supplementary material is available at Crohn’s and Colitis 360 online.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

All authors report no competing interests.

Data availability

The data and materials used in this work are available from the corresponding author upon request.

Ethics approval

The study was conducted in accordance with the international ethical principles of scientific research, including those in the Declaration of Helsinki. Our study was ethically approved by the Institutional Review Board (IRB) at the local IRB [Reference: Med. March. 2025/36]. All participants provided written informed consent prior to participation. For participants aged below 18 years, written informed consent was obtained from a parent or legal guardian, and participant assent was obtained when applicable.

References

1 M’Koma AE.  The multifactorial etiopathogeneses interplay of inflammatory bowel disease: an overview . Gastrointest Disord . 2018 ;1 :75: 105 . 10.3390/GIDISORD1010007 PMC10416806 37577036
2 Guan Q.  A comprehensive review and update on the pathogenesis of inflammatory bowel disease . J Immunol Res . 2019 ;2019 :7247238 . 10.1155/2019/7247238 31886308 PMC6914932
3 Mak WY , Zhao M , Ng SC , Burisch J.  The epidemiology of inflammatory bowel disease: East meets west . J Gastroenterol Hepatol . 2020 ;35 :380: 389 . 10.1111/JGH.14872 31596960
4 Zhao M , Gönczi L , Lakatos PL , Burisch J.  The burden of inflammatory bowel disease in Europe in 2020 . J Crohns Colitis . 2021 ;15 :1573: 1587 . 10.1093/ECCO-JCC/JJAB029 33582812
5 Ng SC , Shi HY , Hamidi N , et al  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies . Lancet . 2017 ;390 :2769: 2778 . 10.1016/S0140-6736(17)32448-0 29050646
6 Zhang Y , Liu J , Han X , et al  Long-term trends in the burden of inflammatory bowel disease in China over three decades: a joinpoint regression and age-period-cohort analysis based on GBD 2019 . Front Public Health . 2022 ;10 :994619 . 10.3389/FPUBH.2022.994619/BIBTEX 36159285 PMC9490087
7 Huppertz-Hauss G , Lie Høivik M , Langholz E , et al  Health-related quality of life in inflammatory bowel disease in a european-wide population-based cohort 10 years after diagnosis . Inflamm Bowel Dis . 2015 ;21 :337: 344 . 10.1097/MIB.0000000000000272 25569735 PMC4345967
8 Bernklev T , Jahnsen J , Lygren I , Henriksen M , Vatn M , Moum B.  Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms . Inflamm Bowel Dis . 2005 ;11 :909: 918 . 10.1097/01.MIB.0000179467.01748.99 16189421
9 Rubin DT , Siegel CA , Kane SV , et al  Impact of ulcerative colitis from patients’ and physicians’ perspectives: Results from the UC: NORMAL survey . Inflamm Bowel Dis . 2009 ;15 :581: 588 . 10.1002/IBD.20793 19067414
10 Ghosh S.  Inflammatory bowel disease: appreciating disability and impact of disease . Can J Gastroenterol Hepatol . 2015 ;29 :66 . 10.1155/2015/189360 25803013 PMC4373561
11 Kobayashi T , Siegmund B , Le Berre C , et al  Ulcerative colitis . Nat Rev Dis Primers . 2020 ;6 :74 . 10.1038/s41572-020-0205-x 32913180
12 Magro F , Gionchetti P , Eliakim R , et al  European Crohn’s and Colitis Organisation [ECCO]. Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders . J Crohns Colitis . 2017 ;11 :649: 670 . 10.1093/ECCO-JCC/JJX008 28158501
13 Ott C , Scholmerich J.  Extraintestinal manifestations and complications in IBD . Nat Rev Gastroenterol Hepatol . 2013 ;10 :585: 595 . 10.1038/NRGASTRO.2013.117 23835489
14 Chan W , Shim HH , Lim MS , et al  Symptoms of anxiety and depression are independently associated with inflammatory bowel disease-related disability . Digestive and Liver Disease . 2017 ;49 :1314: 1319 . 10.1016/j.dld.2017.08.020 28882540
15 Büsch K , Sonnenberg A , Bansback N.  Impact of inflammatory bowel disease on disability . Curr Gastroenterol Rep . 2014 ;16 :414 . 10.1007/S11894-014-0414-0 25231757
16 Allen PB , Gower-Rousseau C , Danese S , Peyrin-Biroulet L.  Preventing disability in inflammatory bowel disease . Therap Adv Gastroenterol . 2017 ;10 :865: 876 . 10.1177/1756283X17732720 29147137 PMC5673018
17 Turner D , Ricciuto A , Lewis A , et al  International Organization for the Study of IBD. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD . Gastroenterology . 2021 ;160 :1570: 1583 . 10.1053/j.gastro.2020.12.031 33359090
18 Tse CS , Hunt MG , Brown LA , Lewis JD.  Inflammatory bowel diseases-related disability: Risk factors, outcomes, and interventions . Inflamm Bowel Dis . 2024 ;30 :501: 507 . 10.1093/IBD/IZAD182 37603844
19 Gower-Rousseau C , Sarter H , Savoye G , et al  Validation of the inflammatory bowel disease disability index in a population-based cohort . Gut . 2017 ;66 :588: 596 . 10.1136/GUTJNL-2015-310151 26646934
20 Ghosh S , Louis E , Beaugerie L , et al  Development of the IBD disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases . Inflamm Bowel Dis . 2017 ;23 :333: 340 . 10.1097/MIB.0000000000001033 28146002 PMC5319390
21 AlMuhaidib S , Bzeizi K , AlAmeel T , et al  A bibliometric analysis of inflammatory bowel disease research in the arab world . Saudi J Gastroenterol . 2025 ;31 :146: 156 . 10.4103/SJG.SJG_303_24 39660608 PMC12155454
22 Meeralam Y , Al-Zanbagi AB , Al Saedi M , et al  IBD-Disk as a tool estimating the prevalence of inflammatory bowel disease-related disability and associated influencing factors in Saudi Arabia: a cross-sectional study . Saudi J Gastroenterol . 2023 ;29 :309: 315 . 10.4103/SJG.SJG_3_23 37787349 PMC10644998
23 Tadbiri S , Nachury M , Bouhnik Y , et al  GETAID-IBD-Disk Study Group. The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease . J Crohns Colitis . 2021 ;15 :766: 773 . 10.1093/ECCO-JCC/JJAA244 33246337
24 Bastida G , Nos P , Aguas M , et al  The effects of thiopurine therapy on health-related quality of life in inflammatory bowel disease patients . BMC Gastroenterol . 2010 ;10 :26 . 10.1186/1471-230X-10-26 20196836 PMC2846867
25 Alruthia Y , Alsharif W , Almuaythir G , et al  P444 the impact of azathioprine on inflammatory bowel disease patients’ overall health-related quality of life: a single-Centre retrospective cohort study . J Crohns Colitis . 2020 ;14 :S400: S401 . 10.1093/ECCO-JCC/JJZ203.573
26 Singh A , Mahajan R , Kedia S , et al  Use of thiopurines in inflammatory bowel disease: an update . Intest Res . 2022 ;20 :11: 30 . 10.5217/IR.2020.00155 33845546 PMC8831775
27 Imbrizi M , Azevedo MFC , Baima JP , et al  Positioning and sequencing of advanced therapies in inflammatory bowel disease: a guide for clinical practice . World J Gastroenterol . 2025 ;31 :107745 . 10.3748/WJG.V31.I29.107745 40809925 PMC12344364
28 Yewale RV , Ramakrishna BS , Doraisamy BV , et al  Long-term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: a real-world experience . JGH Open . 2023 ;7 :599: 609 . 10.1002/JGH3.12955 37744710 PMC10517446
29 Ulitsky A , Ananthakrishnan AN , Naik A , et al  Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life . JPEN J Parenter Enteral Nutr . 2011 ;35 :308: 316 . 10.1177/0148607110381267 21527593
30 Hausmann J , Kubesch A , Amiri M , Filmann N , Blumenstein I.  Vitamin D deficiency is associated with increased disease activity in patients with inflammatory bowel disease . J Clin Med . 2019 ;8 :1319 . 10.3390/JCM8091319 31461996 PMC6780251
31 Reich KM , Fedorak RN , Madsen K , Kroeker KI.  Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review . World J Gastroenterol . 2014 ;20 :4934: 4947 . 10.3748/wjg.v20.i17.4934 24803805 PMC4009525
32 Li J , Chen N , Wang D , Zhang J , Gong X.  Efficacy of vitamin D in treatment of inflammatory bowel disease: a meta-analysis . Medicine (Baltimore) . 2018 ;97 :e12662 . 10.1097/MD.0000000000012662 30431562 PMC6257592
33 Dell’Anna G , Fanizzi F , Zilli A , et al  The role of vitamin D in inflammatory bowel diseases: from deficiency to targeted therapeutics and precise nutrition strategies . Nutrients . 2025 ;17 :2167 . 10.3390/NU17132167 40647273 PMC12252289
34 Aldhous MC , Satsangi J.  The impact of smoking in crohn’s disease: no smoke without fire . Frontline Gastroenterol . 2010 ;1 :156: 164 . 10.1136/FG.2010.001487 28839569 PMC5517176
35 Mínguez A , Nos P.  Association of smoking and crohn’s disease: an update . J Cell Immunol . 2024 ;6 :140: 147 . 10.33696/IMMUNOLOGY.6.200
Publication and source details

Original title: Disability among Palestinian patients with inflammatory bowel disease: evaluation using the IBD Disk and identification of associated factors

Ahmed Quraish; Ro’ya Khanfar; Karmil Kharouf; Sami Salous; Dala Quraish; Qusay Abdoh

Crohn's & Colitis 360 · 2026

Corresponding author: Ahmed Quraish, MD, Department of Scientific Research and Medical Projects, Faculty of Medicine and Allied Medical Sciences, An-Najah National University, Nablus 44839, Palestine (ahmed.a.a.quraish@gmail.com).© The Author(s) 2026. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:06:08.018244+00:00

DOI: 10.1093/crocol/otag079 · PMC13418206